Alkermes plc (ALKS) stock analysis
Healthcare · Drug Manufacturers - Specialty & Generic
From the 10-K filed 2026-02-25
Business type: Franchise
How it makes money
It earns by selling proprietary schizophrenia and addiction treatments like ARISTADA and VIVITROL while collecting royalties from third-party licenses on long-acting INVEGA products.
Physicians prescribe and wholesalers purchase the company's proprietary neuroscience medicines because they offer specialized extended-release formulations for chronic neurological conditions.
Net income is driven by the volume of units sold and periodic price increases, such as the 3% increase implemented in 2025. However, actual earnings are heavily influenced by the gross-to-net spread, as a large portion of gross sales is offset by Medicaid rebates and chargebacks.
What protects it: the moat
The company utilizes proprietary LINKERX and NANOCRYSTAL technologies to create extended-release injectable formulations that management claims are singular or competitively advantaged.
The company relies on its proprietary LINKERX technology, a linker-based prodrug system that allows for enzyme-mediated hydrolysis once inside the body, and its NANOCRYSTAL technology, which enables faster dissolution for rapid drug delivery.
These technologies allow it to offer dosing options ranging from once-monthly to every two months, creating a high barrier for competitors to provide similar long-acting patient convenience without infringing on its specific formulation patents.
What growth costs
It maintains an Ohio manufacturing facility and spent $10.0 million in late 2025 on the acquisition of Avadel Pharmaceuticals to expand its narcolepsy portfolio.
The company must reinvest in clinical development and strategic acquisitions to replace older products. Maintaining its manufacturing facility in Ohio is a structural necessity for its proprietary product line.
A significant recent investment included the Avadel Acquisition for $21.00 per share in cash plus contingent value rights, which was intended to integrate the narcolepsy drug LUMRYZ into its commercial lineup.
What could damage it
Performance suffers when third-party licensees sell long-acting treatments that compete directly for the same patients as the company’s proprietary ARISTADA and LYBALVI.
A primary risk to earnings is the conflict of interest inherent in its licensing model. Major pharmaceutical partners that pay the company royalties also control the marketing of competing long-acting drugs. If these partners prioritize their own similar medicines, it can cannibalize the market share of the company's wholly-owned proprietary brands.
About Alkermes plc
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.